Home NEWS AND MEDIA

NeuExcell Therapeutics raises $10+ million series Pre-A round to continue Its company growth

30 Aug 2021

Related news

05 / Dec 2025

Clinical | NeuExcell Therapeutics Reports Encouraging Clinical Results with In Situ Conversion Therapy for Malignant Glioma
Learn more
11 / Jun 2025

NeuExcell Therapeutics Announces First Dosing of NXL-001 in a Patient with Ten Years of Alzheimer's Disease
Learn more
03 / Jun 2025

NeuExcell Therapeutics' NXL-004 Gene Therapy Shows Positive Early Results in Treating Recurrent Malignant Glioblastoma
Learn more